These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 21723763

  • 1. Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer.
    Sullivan S, Wagner J, Resnick NM, Nelson J, Perera SK, Greenspan SL.
    J Clin Densitom; 2011; 14(3):348-53. PubMed ID: 21723763
    [Abstract] [Full Text] [Related]

  • 2. Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.
    Greenspan SL, Wagner J, Nelson JB, Perera S, Britton C, Resnick NM.
    J Bone Miner Res; 2013 Feb; 28(2):325-32. PubMed ID: 22991066
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vertebral fracture assessment by DXA is inferior to X-ray in clinical severe osteoporosis.
    Deleskog L, Laursen NØ, Nielsen BR, Schwarz P.
    Osteoporos Int; 2016 Jul; 27(7):2317-2326. PubMed ID: 26892040
    [Abstract] [Full Text] [Related]

  • 6. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME, Pundole X, Cabanillas G, Lei X, Zhao H, Elting LS, Lopez-Olivo MA, Giordano SH.
    JAMA Netw Open; 2022 Apr 01; 5(4):e225432. PubMed ID: 35363269
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM, Ma JZ, Basler JW, Welch MD.
    Urology; 2006 Jan 01; 67(1):152-5. PubMed ID: 16413352
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.
    Adler RA, Hastings FW, Petkov VI.
    Osteoporos Int; 2010 Apr 01; 21(4):647-53. PubMed ID: 19533207
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH, Frost M, Abrahamsen B, Brixen K, Walter S.
    Scand J Urol; 2014 Aug 01; 48(4):350-5. PubMed ID: 24548220
    [Abstract] [Full Text] [Related]

  • 17. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.
    Med J Aust; 2011 Mar 21; 194(6):301-6. PubMed ID: 21426285
    [Abstract] [Full Text] [Related]

  • 18. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ, Srinivas S, Perkash I, Terris MK.
    Urology; 2001 Jan 21; 57(1):127-32. PubMed ID: 11164157
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
    Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS.
    J Clin Oncol; 2012 May 20; 30(15):1864-70. PubMed ID: 22493411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.